{"schema_version":"1","generated_at":"2026-10-31T02:03:37.043Z","data_as_of":null,"url":"https://www.findmykol.com/kol/anil-sood","json_url":"https://www.findmykol.com/kol/anil-sood/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"anil-sood","name":"Anil Sood","credential":"MD","specialty":"Gynecologic Oncology","specialty_raw":"Gynecologic Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"The University of Texas MD Anderson Cancer Center","institution_url":"https://www.findmykol.com/institution/the-university-of-texas-md-anderson-cancer-center","city":"Houston","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1184720906","orcid":"0000-0002-5415-9901","openalex":"A5100640276"},"summary":"Anil Sood is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 2,586 publications with 133,006 citations (h-index 158); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 1% of Gynecologic Oncology profiles in the FindMyKOL directory.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":2586,"cited_by_count":133006,"h_index":158,"latest_activity_year":2026,"citation_standing":{"top_percent":1,"cohort":"Gynecologic Oncology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT02923739","title":"Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT02923739","trial_url":"https://www.findmykol.com/trial/NCT02923739"},{"nct":"NCT01097746","title":"First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT01097746","trial_url":"https://www.findmykol.com/trial/NCT01097746"}],"source":"trials"},"payments":{"company_count":11,"program_years":{"first":2021,"last":null},"rows_total":16,"shown":3,"withheld":13,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":71.18,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1184720906"},{"payer":"Corcept Therapeutics","program_year":2025,"amount_usd":51.67,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1184720906"},{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":46.83,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1184720906"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1184720906","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cancer & immunology","share_pct":100,"classes_total":1,"classes":[{"class":"Poly(ADP-Ribose) Polymerase Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Zejula","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":19,"fiscal_years":{"first":2004,"last":2026},"rows_total":140,"shown":3,"withheld":137,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"P50CA281701","title":"The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer","fiscal_year":2026,"amount_usd":"2288869","organization":"UNIVERSITY OF TX MD ANDERSON CAN CTR","source_url":"https://reporter.nih.gov/quickSearch/P50CA281701"},{"project":"R01CA306089","title":"Development of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian Cancer","fiscal_year":2026,"amount_usd":"667315","organization":"BAYLOR COLLEGE OF MEDICINE","source_url":"https://reporter.nih.gov/quickSearch/R01CA306089"},{"project":"T32CA101642","title":"Training of Academic Gynecologic Oncologists","fiscal_year":2026,"amount_usd":"567034","organization":"UNIVERSITY OF TX MD ANDERSON CAN CTR","source_url":"https://reporter.nih.gov/quickSearch/T32CA101642"}],"source":"grants"},"contact":{"address_1":"1515 HOLCOMBE BLVD","city":"Houston","state":"TX","zip":"77030","phone":"713-792-6161","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1184720906","source":"identity"},"similar":[{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Funda Meric-Bernstam","slug":"funda-meric-bernstam","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Surgery","url":"https://www.findmykol.com/kol/funda-meric-bernstam","json_url":"https://www.findmykol.com/kol/funda-meric-bernstam/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":13,"funding":137}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2018-08-30","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}